Upstream Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UPB research report →
About the company
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor.
- CEO
- E. Rand Sutherland
- IPO
- 2024
- Employees
- 52
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $408.69M
- P/E
- -2.58
- P/S
- 123.03
- P/B
- 1.34
- EV/EBITDA
- -2.00
- Div Yield
- 0.00%
- Gross Margin
- 98.52%
- Op Margin
- -5176.49%
- Net Margin
- -4718.96%
- ROE
- -43.82%
- ROIC
- -56.36%
- Revenue
- $2.85M · 20.42%
- Net Income
- $-143,443,000 · -128.39%
- EPS
- $-2.66 · -78.52%
- Op Income
- $-160,361,000
- FCF YoY
- -123.30%
- 52W High
- $33.68
- 52W Low
- $5.85
- 50D MA
- $7.91
- 200D MA
- $17.06
- Beta
- 1.24
- Avg Volume
- 603.76K
Get TickerSpark's AI analysis on UPB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | GRAY MICHAEL | sell | 853 |
| Jun 16, 26 | Sutherland Everett Rand | sell | 2,095 |
| Jun 16, 26 | Houghton Adam | sell | 700 |
| Jun 16, 26 | Deykin Aaron | sell | 895 |
| Jun 16, 26 | Ambrose Allison | sell | 477 |
| Jun 9, 26 | Ruddy Marcella K. | other | 17,096 |
| Jun 9, 26 | Renaud Ronald C JR | other | 17,096 |
| Jun 9, 26 | Fleming Harold Edward | other | 17,096 |
| Jun 9, 26 | Beckman Daniella | other | 17,096 |
| Jun 9, 26 | Ratcliffe Liam | other | 17,096 |
Our UPB coverage
Recent articles, reports, and earnings notes.
No research on UPB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UPB report →Similar companies
Peers in the same neighborhood.